Expectations Rising for Kura Oncology’s (KURA) Drug; Aegean Marine Petroleum (ANW) Beats Estimates
Kura Oncology, Inc. (Nasdaq:KURA) stock surged 1.87% (or +$0.08) to $4.36 with a total volume of 118,676 shares traded on Wednesday.
After the closing bell, the clinical stage biopharmaceutical company reported second quarter 2016 net loss of ($6.7) million, or ($0.36) per share versus a net loss of ($5.6) million, or ($0.54) per share in the same quarter of the last year. Kura also said that positive clinical activity has been observed in the three patients participating in its ongoing trial evaluating tipifarnib – an inhibitor of protein farnesylation – in HRAS mutant solid tumors, sending its stock up over 35% in the extended session.
Kura Oncology, which engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers, has 21.37M Shares Outstanding, Market Capitalization (intraday) of $91.47M and KURA stock range – from November 03, 2015 to date – is between $2.50 and $14.00 per share.
Shares of Aegean Marine Petroleum Network Inc. (NYSE:ANW) soared more than 15% in after-hours trading Wednesday as the company delivered stronger-than-expected profit and revenue numbers in its quarterly financial results
For the second quarter 2016, the international marine fuel logistics company posted revenue of $987.6 million and adjusted net income of $16.0 million, or $0.32 per diluted share, topping the Capital IQ Consensus Estimate of $0.23 earnings per share on revenues of $938.48 million for the period
ANW stock closed the regular session in negative territory by 0.30% (or -0.02) at $6.59 and 224,259 of its shares changed hands during the day
Aegean Marine Petroleum Network, which markets and physically supplies refined marine fuel and lubricants to ships in port and at sea, has 50.04M Shares Outstanding, Market Capitalization (intraday) of $321.95M and ANW stock 52-week range is from $5.00 to $11.85 per share
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/